Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia.
Anal cancer
Anogenital area
HPV-related cancers
Multiple subsequent cancers
Vaginal cancer
Vulvar cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
13
02
2020
accepted:
22
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
23
4
2021
Statut:
epublish
Résumé
The aim was to estimate the risk of subsequent extra-cervical Human Papillomavirus (HPV) related cancer in patients surgically treated for high grade cervical intraepithelial neoplasia (CIN 2-3). This is the first study in Italy investigating the occurrence of extra-cervical tumors in this cohort of patients. 3184 patients surgically treated for CIN2-3 since 1992 at the Department of Surgical Sciences of University of Torino were considered. The risk of HPV-related cancer was calculated as Standardized Incidence Ratio (SIR), using as expected values tumour age specific incidence of resident population. 173 second primary cancer (SCPs) were identified. SIR to develop cancer after treatment for CIN2-3 was 2.2 (CI 95% 1.89-2.50). Among these occurrences, 10 are in HPV related sites: 1 anus (SIR = 1.8; 0.04-10.0), 3 vagina (SIR = 12.4; 2.56-36.3), 1 vulva (SIR = 1.7; 0.04-9.59), 5 oropharynx (SIR = 8.5; 2.76-19.8). Significant risk has been also recorded for pulmonary (SIR = 3.1; 0.70-5.27) and bladder (SIR = 4.05; 1.10-10.56), with smoking as possible cofactor. We also found increased risk for breast (SIR = 2.4; 2.07-2.84) and ovarian cancers (SIR = 2.1; 1.13-3.49), probably due to an higher adherence to spontaneous and programmed screening programs. Our study supports the hypothesis of an increased risk of HPV-related tumours for CIN treated patients, mostly for CIN3. It is conceivable the need of early diagnosis for these cancers in this higher-risk populations.
Sections du résumé
BACKGROUND
BACKGROUND
The aim was to estimate the risk of subsequent extra-cervical Human Papillomavirus (HPV) related cancer in patients surgically treated for high grade cervical intraepithelial neoplasia (CIN 2-3). This is the first study in Italy investigating the occurrence of extra-cervical tumors in this cohort of patients.
METHODS
METHODS
3184 patients surgically treated for CIN2-3 since 1992 at the Department of Surgical Sciences of University of Torino were considered. The risk of HPV-related cancer was calculated as Standardized Incidence Ratio (SIR), using as expected values tumour age specific incidence of resident population.
RESULTS
RESULTS
173 second primary cancer (SCPs) were identified. SIR to develop cancer after treatment for CIN2-3 was 2.2 (CI 95% 1.89-2.50). Among these occurrences, 10 are in HPV related sites: 1 anus (SIR = 1.8; 0.04-10.0), 3 vagina (SIR = 12.4; 2.56-36.3), 1 vulva (SIR = 1.7; 0.04-9.59), 5 oropharynx (SIR = 8.5; 2.76-19.8). Significant risk has been also recorded for pulmonary (SIR = 3.1; 0.70-5.27) and bladder (SIR = 4.05; 1.10-10.56), with smoking as possible cofactor. We also found increased risk for breast (SIR = 2.4; 2.07-2.84) and ovarian cancers (SIR = 2.1; 1.13-3.49), probably due to an higher adherence to spontaneous and programmed screening programs.
CONCLUSIONS
CONCLUSIONS
Our study supports the hypothesis of an increased risk of HPV-related tumours for CIN treated patients, mostly for CIN3. It is conceivable the need of early diagnosis for these cancers in this higher-risk populations.
Identifiants
pubmed: 33028248
doi: 10.1186/s12885-020-07452-6
pii: 10.1186/s12885-020-07452-6
pmc: PMC7542855
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
972Références
Ann Oncol. 2020 Feb;31(2):213-227
pubmed: 31959338
J Low Genit Tract Dis. 2020 Jan;24(1):75-81
pubmed: 31860580
Neoplasma. 2015;62(2):308-14
pubmed: 25591597
PLoS One. 2015 Apr 01;10(4):e0123029
pubmed: 25830243
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Acta Oncol. 2019 Mar;58(3):265-266
pubmed: 30821615
Medicina (Kaunas). 2019 Jul 17;55(7):
pubmed: 31319555
PLoS One. 2018 Oct 5;13(10):e0205077
pubmed: 30289952
Cancer. 2003 Mar 15;97(6):1558-63
pubmed: 12627521
Lancet Oncol. 2007 Apr;8(4):311-6
pubmed: 17395104
Prev Med. 2016 Sep;90:52-8
pubmed: 27370167
BMJ. 2007 Nov 24;335(7629):1077
pubmed: 17959735
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Curr Opin Virol. 2017 Oct;26:56-62
pubmed: 28778034
BMC Res Notes. 2015 Nov 27;8:730
pubmed: 26613933
Cancer Cytopathol. 2011 Feb 25;119(1):5-19
pubmed: 21319310
Viruses. 2015 Jul 16;7(7):3863-90
pubmed: 26193301
BMJ. 2005 Nov 19;331(7526):1183-5
pubmed: 16293840
Semin Cancer Biol. 2014 Jun;26:13-21
pubmed: 24316445
Obstet Gynecol. 2020 May;135(5):1070-1083
pubmed: 32282601
J Low Genit Tract Dis. 2018 Jul;22(3):225-230
pubmed: 29649025
Occup Environ Med. 2020 May 8;:
pubmed: 32385189
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1090-7
pubmed: 27358257
Gynecol Oncol. 2014 Sep;134(3):523-6
pubmed: 25042671
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:14-26
pubmed: 29037457
JAMA Netw Open. 2018 Sep 7;1(5):e181999
pubmed: 30646145
Oncotarget. 2017 Oct 9;8(56):96419-96432
pubmed: 29221217
J Clin Oncol. 2017 Aug 1;35(22):2542-2550
pubmed: 28541790
Gynecol Oncol. 2020 May;157(2):456-462
pubmed: 32008794
Biomed Pharmacother. 2018 Oct;106:1537-1556
pubmed: 30119229
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13
pubmed: 28964706
Cancer Treat Res Commun. 2019;19:100122
pubmed: 30785026
Cancers Head Neck. 2018 Dec 29;3:12
pubmed: 31093365
J Low Genit Tract Dis. 2012 Oct;16(4):454-9
pubmed: 22968054
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:27-41
pubmed: 28919159
Cancer Epidemiol. 2020 Feb;64:101649
pubmed: 31816512
Sci Rep. 2019 Jul 5;9(1):9729
pubmed: 31278284
Int J Gynecol Pathol. 2007 Oct;26(4):441-6
pubmed: 17885496
Gynecol Oncol. 2003 Jul;90(1):131-6
pubmed: 12821353
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:86-94
pubmed: 29030149
J Cancer Educ. 2020 Jun;35(3):606-615
pubmed: 30850945
Papillomavirus Res. 2018 Jun;5:38-45
pubmed: 29272853
BMC Health Serv Res. 2016 Jun 27;16:206
pubmed: 27349646
Gynecol Oncol. 2013 Feb;128(2):265-70
pubmed: 23146688
Obstet Gynecol. 2011 Mar;117(3):643-9
pubmed: 21343768